Forensic accounting review and revenue recognition transparency audit for ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Forensic accounting review and revenue recognition transparency audit for ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Forensic financial review and accounting transparency profiling for ALNYLAM PHARMACEUTICALS, INC. (ticker ALNY) scrutinizes audited 10-K and 10-Q periodic filings, focusing on revenue recognition policies, accounts receivable velocity, and accrual ratios. Analyzing operational cash flow reconciliation against reported GAAP net income confirms the fundamental quality and sustainability of corporate earnings within the BIOTECH_FDA marketplace.
Verified Quantitative Data
| Metric | Value |
|---|---|
| Is Cross | false |
| Has Whale | true |
| Has Congress | true |
| Has Contract | false |
| Darkpool Ratio | 0.6717 |
Full trading intelligence, federal contract history and congressional flow for ALNY.
Primary Source Record
This fact is compiled from public federal disclosure records. Explore the underlying dataset on the Federal Contract Explorer and the Capitol Trades leaderboard.
Data intelligence from public filings — not investment advice.